Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
or

Akebia Therapeutics (AKBA)

Akebia Therapeutics (AKBA)
2.01 x 1 2.12 x 5
Post-market by (Cboe BZX)
2.06 +0.16 (+8.42%) 04/17/25 [NASDAQ]
2.01 x 1 2.12 x 5
Post-market 2.07 +0.01 (+0.49%) 19:54 ET
Quote Overview for Thu, Apr 17th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.90
Day High
2.13
Open 1.90
Previous Close 1.90 1.90
Volume 4,591,200 4,591,200
Avg Vol 4,965,220 4,965,220
Stochastic %K 82.70% 82.70%
Weighted Alpha +25.56 +25.56
5-Day Change +0.51 (+32.90%) +0.51 (+32.90%)
52-Week Range 0.80 - 2.89 0.80 - 2.89
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 486,636
  • Shares Outstanding, K 236,231
  • Annual Sales, $ 160,180 K
  • Annual Income, $ -69,410 K
  • EBIT $ -50 M
  • EBITDA $ -9 M
  • 60-Month Beta 0.87
  • Price/Sales 2.80
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 89.10% ( -32.77%)
  • Historical Volatility 152.39%
  • IV Percentile 59%
  • IV Rank 21.06%
  • IV High 311.38% on 04/10/25
  • IV Low 29.81% on 08/21/24
  • Put/Call Vol Ratio 0.70
  • Today's Volume 5,550
  • Volume Avg (30-Day) 1,993
  • Put/Call OI Ratio 0.25
  • Today's Open Interest 41,317
  • Open Int (30-Day) 37,979

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.03
  • Number of Estimates 3
  • High Estimate -0.02
  • Low Estimate -0.04
  • Prior Year -0.09
  • Growth Rate Est. (year over year) +66.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.52 +35.53%
on 04/10/25
Period Open: 2.40
2.89 -28.72%
on 03/19/25
-0.34 (-14.17%)
since 03/17/25
3-Month
1.52 +35.53%
on 04/10/25
Period Open: 2.07
2.89 -28.72%
on 03/19/25
-0.01 (-0.48%)
since 01/17/25
52-Week
0.80 +157.50%
on 06/26/24
Period Open: 1.39
2.89 -28.72%
on 03/19/25
+0.67 (+48.20%)
since 04/17/24

Most Recent Stories

More News
Why You Shouldn't Bet Against Akebia Therapeutics (AKBA) Stock

One stock that might be an intriguing choice for investors right now is Akebia Therapeutics, Inc. AKBA. This is because this security in the Medical - Drugs space is seeing solid earnings estimate revision...

AKBA : 2.06 (+8.42%)
Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa

AKBA : 2.06 (+8.42%)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AKBA : 2.06 (+8.42%)
Analysts Love These 2 Growth Stocks That Have Over 200% Upside Potential

Wall Street expects both of these biotech stocks to soar over 200% in the next 12 months.

AKBA : 2.06 (+8.42%)
STOK : 7.69 (+1.72%)
ACAD : 14.73 (+1.10%)
BIIB : 118.61 (+2.88%)
Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025

AKBA : 2.06 (+8.42%)
Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering

Akebia Therapeutics AKBA recently announced that it is floating a secondary issue of 25 million shares of its common stock to the public at an issue price of $2 per share, amounting to $50 million.The...

CTMX : 0.6560 (+4.18%)
ETNB : 6.06 (+2.89%)
AKBA : 2.06 (+8.42%)
ANIP : 69.21 (+0.01%)
Akebia Therapeutics Announces Pricing of Public Offering of Common Stock

AKBA : 2.06 (+8.42%)
Akebia Therapeutics Announces Proposed Public Offering of Common Stock

AKBA : 2.06 (+8.42%)
Akebia Therapeutics: Q4 Earnings Snapshot

Akebia Therapeutics: Q4 Earnings Snapshot

AKBA : 2.06 (+8.42%)
Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update

AKBA : 2.06 (+8.42%)

Business Summary

Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 2.39
2nd Resistance Point 2.26
1st Resistance Point 2.16
Last Price 2.06
1st Support Level 1.93
2nd Support Level 1.80
3rd Support Level 1.70

See More

52-Week High 2.89
Fibonacci 61.8% 2.09
Last Price 2.06
Fibonacci 50% 1.85
Fibonacci 38.2% 1.60
52-Week Low 0.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro